Marlena Broncel, Magdalena Balcerak, Julita Chojnowska-Jezierska

Porównanie wpływu atorwastatyny i ciprofibratu na stężenie CRP, fibrynogenu, kwasu moczowego i glukozy u pacjentów z zespołem metabolicznym
2006-12-01

Comparative effects of atorvastatin and ciprofibrate on CRP, fibrinogen, uric acid and glucose levels in patients with metabolic syndrome. The metabolic syndrome (MS) is associated with excess risk for coronary heart disease and mortality. The aim of the study was to compare the effects of ciprofibrate and atorvastatin on C-reactive protein (CRP) and fibrinogen (Fb) levels in patients (pts) with MS. The study comparised 58 pts, including 38 pts with MS (visceral obesity, mild hypertension, triglicerydes level (TG) >150 mg/dl, cholesterol HDL - HDL-C <40 mg/dl for men, <50 mg/dl for women) and 20 healthy volunteers. Pts with MS were randomized to two groups: I ń 20 pts treated with atorvastatin (20 mg/24h); II ń 18 pts - ciprofibrate (100 mg/24h). Before, after 1 and 6 months of active treatment the following parameters were determined: lipids, glucose, uric acid level (by enzymatic method using bioMerieux tests), CRP (by immunoturbidimetric method), fibrinogen (by Claussí method). It was noticed significantly higher concentrations of CRP, Fb, uric acid and glucose in pts with MS than in the control group. The both examined drugs caused a significant decrease in CRP, Fb after 6 months of therapy. Additionally ciprofibrate significantly decreased glucose levels. The anti-inflammatory effects of atorvastatin was observed earlier (after 1 month therapy) than ciprofibrate.